Welcome to our dedicated page for Chimera Invt SEC filings (Ticker: CIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chimera Investment Corp. filings document the disclosure record of a Maryland real estate investment trust with common stock, multiple preferred stock series, and senior notes listed on the New York Stock Exchange. Form 8-K reports cover results of operations, investor presentation materials, Regulation FD updates, and dividend announcements tied to the company's mortgage-asset investment and origination business.
The filing record also includes definitive proxy materials for shareholder voting and governance matters. Chimera's securities disclosures identify its common stock, Series A through Series D preferred stock, and senior notes due 2029 and 2030, reflecting the capital structure used alongside its residential mortgage loans, RMBS, MSRs, business purpose loans, investor loans, and related real estate assets.
Mills Susan reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Susan Mills reported an award of 11,263 restricted stock units (RSUs) tied to Chimera common stock. Each RSU is economically equivalent to one share of common stock and is scheduled to vest on the earlier of June 11, 2027 or the next annual stockholders meeting. The award will be settled entirely in shares of Chimera common stock. Following this grant, Mills reports beneficial ownership of 37,757 shares, including the RSUs.
STILL DEBRA reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Debra Still received a grant of 11,263 restricted stock units (RSUs) of common stock as compensation. The award was recorded at a price of $0.00 per share, indicating a non-cash equity grant rather than an open-market purchase.
The RSUs are scheduled to vest on the earlier of the first anniversary of the grant date on June 11, 2027, or the date of Chimera’s next annual stockholders meeting, and will be settled entirely in shares of Chimera common stock. After this grant, Still directly holds 60,706 shares of Chimera common stock. Each RSU has the economic equivalent of one share of Chimera common stock.
Chavers Kevin Gerald reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Kevin Gerald Chavers reported an equity award of 11,263 restricted stock units (RSUs) tied to Chimera common stock. The RSUs, each economically equal to one share, were granted at no cash cost and will vest on the earlier of the first anniversary of the June 11, 2026 grant date or the next annual stockholders meeting, then be settled entirely in shares. After this grant, Chavers holds 50,506 shares of Chimera common stock.
Walsh Cynthia B reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Cynthia B. Walsh received an equity award of 11,263 shares of common stock in the form of restricted stock units (RSUs). The grant was made at a stated price of $0.00 per share as a compensation award, not an open-market purchase.
The RSUs are scheduled to vest on the earlier of the first anniversary of the grant date, June 11, 2027, or the date of Chimera’s next annual stockholders meeting, and will be settled entirely in Chimera common stock on vesting. Following this grant, Walsh directly holds 26,765 shares of Chimera common stock, including the unvested RSUs. Each RSU has the economic equivalent of one share of Chimera common stock.
Reilly Brian Patrick reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Brian Patrick Reilly received an equity grant of 11,263 restricted stock units (RSUs) of common stock. The RSUs vest on the earlier of the first anniversary of the June 11, 2026 grant date or the next annual stockholders meeting and will be settled entirely in Chimera common shares. After this award, Reilly holds 106,133 shares of common stock, reflecting a compensation-related grant rather than an open-market purchase.
CREAGH GERARD reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Gerard Creagh received an equity award of 11,263 restricted stock units (RSUs) on Chimera common stock. The RSUs are scheduled to vest on the earlier of the first anniversary of the grant date on June 11, 2027, or the date of Chimera’s next annual stockholders meeting, and will be settled entirely in shares of common stock. After this grant, Creagh directly holds 188,015 shares of Chimera common stock. This is a compensation-related grant rather than an open‑market purchase.
Chimera Investment Corporation held its 2026 annual stockholders meeting, where all management proposals passed with strong support. Holders of 63,285,465 of 83,645,571 common shares entitled to vote, or about 75.65%, were represented in person or by proxy.
Stockholders elected Class I directors Kevin G. Chavers, Gerard Creagh and Susan Mills to serve until the 2029 annual meeting. A non-binding advisory resolution approving the company’s executive compensation received 42,287,598 votes for versus 1,901,663 against. Stockholders also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.
Chimera Investment Corporation declared a second quarter 2026 cash dividend of $0.45 per common share. This matches its first quarter 2026 dividend and aligns with the Board’s previously stated expectation to maintain a $0.45 quarterly dividend throughout 2026, implying $1.80 per share on an annualized basis.
The dividend is payable on July 31, 2026 to common shareholders of record on June 30, 2026, with an ex-dividend date of June 30, 2026. The update was furnished under Regulation FD to keep investors informed about the company’s ongoing cash return policy.
Chimera Investment Corporation reported a net loss of $43.9 million for the quarter ended March 31, 2026, versus net income of $167.3 million a year earlier. Net interest income rose to $75.0 million, but large unrealized and realized losses on financial instruments and debt extinguishment pushed results negative.
Net income (loss) available to common shareholders was $(65.0) million, or $(0.78) per basic share, compared with $145.9 million or $1.79 per share in 2025. Total assets were $16.0 billion, stockholders’ equity was $2.46 billion, and common shares outstanding were 83.6 million as of April 30, 2026.
Chimera Investment Corporation reported a net loss of $43.9 million for the quarter ended March 31, 2026, versus net income of $167.3 million a year earlier. Net interest income rose to $75.0 million, but large unrealized and realized losses on financial instruments and debt extinguishment pushed results negative.
Net income (loss) available to common shareholders was $(65.0) million, or $(0.78) per basic share, compared with $145.9 million or $1.79 per share in 2025. Total assets were $16.0 billion, stockholders’ equity was $2.46 billion, and common shares outstanding were 83.6 million as of April 30, 2026.
Chimera Investment Corporation announced second quarter 2026 cash dividends on all four series of its preferred stock. The Board declared $0.50 per share for the 8.00% Series A Cumulative Redeemable Preferred Stock.
For the fixed-to-floating series, Chimera declared $0.6095 per share on the 8.00% Series B, $0.5561 per share on the 7.75% Series C, and $0.5967 per share on the 8.00% Series D preferred stock. These dividends, reflecting annualized rates tied to three-month CME Term SOFR plus stated spreads, are payable on June 30, 2026 to shareholders of record on June 1, 2026, with an ex-dividend date of June 1, 2026.
Chimera Investment Corporation announced second quarter 2026 cash dividends on all four series of its preferred stock. The Board declared $0.50 per share for the 8.00% Series A Cumulative Redeemable Preferred Stock.
For the fixed-to-floating series, Chimera declared $0.6095 per share on the 8.00% Series B, $0.5561 per share on the 7.75% Series C, and $0.5967 per share on the 8.00% Series D preferred stock. These dividends, reflecting annualized rates tied to three-month CME Term SOFR plus stated spreads, are payable on June 30, 2026 to shareholders of record on June 1, 2026, with an ex-dividend date of June 1, 2026.